Search results for "Type 2"

showing 10 items of 1034 documents

The Mitochondria-Targeted Antioxidant MitoQ Modulates Mitochondrial Function and Endoplasmic Reticulum Stress in Pancreatic β Cells Exposed to Hyperg…

2019

Background/aims Mitochondria-targeted antioxidants such as mitoquinone (MitoQ) have demonstrated protective effects against oxidative damage in several diseases. The increase in reactive oxygen species (ROS) production during glucose metabolism in β cells can be exacerbated under hyperglycaemic conditions such as type 2 diabetes (T2D), thus contributing to β cell function impairment. In the present work, we aimed to evaluate the effect of MitoQ on insulin secretion, oxidative stress, endoplasmic reticulum (ER) stress and nuclear factor kappa B (NFκB) signalling in a pancreatic β cell line under normoglycaemic (NG, 11.1 mM glucose), hyperglycaemic (HG, 25 mM glucose) and lipidic (palmitic ac…

0301 basic medicinemedicine.medical_specialtyPhysiologyUbiquinoneCarbohydrate metabolismmedicine.disease_causeMitoQlcsh:PhysiologyPancreatic β cellsAntioxidantsProinflammatory cytokinelcsh:Biochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOrganophosphorus CompoundsInternal medicineCell Line TumorInsulin-Secreting CellsmedicineAnimalslcsh:QD415-436chemistry.chemical_classificationReactive oxygen speciesMitoQlcsh:QP1-981Endoplasmic reticulumGlutathioneEndoplasmic Reticulum StressType 2 DiabetesMitochondriaRatsOxidative Stress030104 developmental biologyEndocrinologyGlucosechemistry030220 oncology & carcinogenesisHyperglycemiaUnfolded protein responseER stressMitochondrial dysfunctionReactive Oxygen SpeciesOxidative stressSignal Transduction
researchProduct

Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases.

2016

Background: Due to the continuing increase of the elderly population in the western countries, the prevalence of the main chronic diseases (obesity, type 2 diabetes and related metabolic disorders, arterial hypertension, vascular damage due to atherosclerotic process, cancer, chronic obstructive pulmonary disease, neurodegenerative diseases, chronic kidney disease, immune-mediated diseases) is increasing. There is incontrovertible evidence that regular physical activity contributes to the primary and secondary prevention of several chronic diseases and is associated with a reduced risk of premature death. Methods: In this review the most prevalent chronic pathologic conditions are discussed…

0301 basic medicinemedicine.medical_specialtyPopulationPsychological interventionType 2 diabetes01 natural sciences03 medical and health sciencesMetabolic DiseasesIntervention (counseling)NeoplasmsDrug DiscoverymedicineAnimalsHumansObesity0101 mathematicseducationIntensive care medicineExercisePhysical activity - Chronic diseasesPharmacologyeducation.field_of_studybusiness.industryCancermedicine.diseaseObesity010101 applied mathematics030104 developmental biologyDiabetes Mellitus Type 2Lifestyle changeChronic DiseasePhysical therapybusinessKidney diseaseMuscle ContractionCurrent pharmaceutical design
researchProduct

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Atorvastatin but not pravastatin impairs mitochondrial function in human pancreatic islets and rat β-cells. Direct effect of oxidative stress

2017

AbstractStatins are a class of drugs widely prescribed as frontline therapy for lowering plasma LDL-cholesterol in cardiovascular risk prevention. Several clinical reports have recently suggested an increased risk of type 2 diabetes associated with chronic use of these drugs. The pathophysiology of this effect remains to be fully elucidated but impaired β-cell function constitutes a potential mechanism. The aim of this study was to explore the effect of a chronic treatment with lipophilic and hydrophilic statins on β-cell function, using human pancreatic islets and rat insulin-secreting INS-1 cells; we particularly focused on the role of mitochondria and oxidative stress. The present study …

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_classmedicine.medical_treatmentAtorvastatinPancreatic isletslcsh:MedicineType 2 diabetes030204 cardiovascular system & hematologyMitochondrionPharmacologymedicine.disease_causeArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicinelcsh:ScienceMultidisciplinarybusiness.industryPancreatic isletsInsulinlcsh:RStatinmedicine.disease030104 developmental biologyEndocrinologymedicine.anatomical_structurelcsh:Qlipids (amino acids peptides and proteins)Statins; Pancreatic isletsbusinessOxidative stressPravastatinmedicine.drug
researchProduct

Urinary Bladder Weight and Function in a Rat Model of Mild Hyperglycemia and Its Treatment With Dapagliflozin

2019

Hypertrophy and dysfunction of the urinary bladder are consistently observed in animal models of type 1 and less consistently in those of type 2 diabetes. We have tested the effects of mild hyperglycemia (n = 10 per group) in a randomized, blinded study and, in a blinded pilot study, of type 2 diabetes (n = 6 per group) and its treatment with dapagliflozin (1 mg/kg per day) on weight, contraction, and relaxation of the rat bladder. Based on a combination of high-fat diet and a low dose of streptozotocin, animals in the main study reached a mean peak blood glucose level of about 300 mg/dl, which declined to 205 mg/dl at study end. This was associated with a small, if any, increase in bladder…

0301 basic medicinemedicine.medical_specialtyType 2 diabetesMuscle hypertrophyContractility03 medical and health scienceschemistry.chemical_compound0302 clinical medicinerelaxationDiabetes mellitusInternal medicineMedicinePharmacology (medical)DapagliflozinFenoterolOriginal ResearchPharmacologyUrinary bladderdiabetesbusiness.industrylcsh:RM1-950contractionmedicine.diseaseStreptozotocin030104 developmental biologymedicine.anatomical_structureEndocrinologylcsh:Therapeutics. Pharmacologychemistry030220 oncology & carcinogenesishyperglycemiabusinesshypertrophyurinary bladdermedicine.drugFrontiers in Pharmacology
researchProduct

Magnesium and health outcomes: An umbrella review of systematic reviews and meta-analyses of observational and intervention studies

2020

Purpose: To map and grade all health outcomes associated with magnesium (Mg) intake and supplementation using an umbrella review. Methods: Umbrella review of systematic reviews with meta-analyses of observational studies and randomized controlled trials (RCTs) using placebo/no intervention as control group. We assessed meta-analyses of observational studies based on random-effect summary effect sizes and their p values, 95% prediction intervals, heterogeneity, small-study effects and excess significance. For meta-analyses of RCTs, outcomes with a random-effect p value < 0.005 and a high-GRADE assessment were classified as strong evidence. Results: From 2048 abstracts, 16 meta-analyses an…

0301 basic medicinemedicine.medical_specialtyUmbrella review.Settore MED/09 - Medicina InternaHealth StatusMedicine (miscellaneous)030209 endocrinology & metabolismType 2 diabetesPlaceboDiabetelaw.inventionMagnesium Meta-analysis Pregnancy Diabetes Stroke Umbrella reviewUmbrella review03 medical and health sciences0302 clinical medicineRandomized controlled triallawPregnancyInternal medicinemedicineHumansMeta-analysiMagnesiumStroke030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryDiabetesmedicine.diseaseStrokeMeta-analysisObservational Studies as TopicSystematic reviewMigraineMeta-analysisDietary SupplementsObservational studybusiness
researchProduct

Mitochondrial DNA Haplogroup JT is Related to Impaired Glycaemic Control and Renal Function in Type 2 Diabetic Patients

2018

The association between mitochondrial DNA (mtDNA) haplogroup and risk of type 2 diabetes (T2D) is undetermined and controversial. This study aims to evaluate the impact of the main mtDNA haplogroups on glycaemic control and renal function in a Spanish population of 303 T2D patients and 153 healthy controls. Anthropometrical and metabolic parameters were assessed and mtDNA haplogroup was determined in each individual. Distribution of the different haplogroups was similar in diabetic and healthy populations and, as expected, T2D patients showed poorer glycaemic control and renal function than controls. T2D patients belonging to the JT haplogroup (polymorphism m.4216T&gt

0301 basic medicinemedicine.medical_specialtyendocrine system diseasesgenetic structurestype 2 diabetes mellituslcsh:MedicineRenal functionType 2 diabetesArticleHaplogroupNephropathyDiabetic nephropathy03 medical and health scienceschemistry.chemical_compoundInternal medicineMedicineCreatininebusiness.industrymtDNAlcsh:Rmitochondrial haplogroupType 2 Diabetes Mellitusnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseeye diseaseshumanities030104 developmental biologyEndocrinologychemistryglycemic controlnephropathybusinessHuman mitochondrial DNA haplogroup
researchProduct

Insulin resistance and diabetes in hyperthyroidism: a possible role for oxygen and nitrogen reactive species.

2019

In addition to insulin, glycemic control involves thyroid hormones. However, an excess of thyroid hormone can disturb the blood glucose equilibrium, leading to alterations of carbohydrate metabolism and, eventually, diabetes. Indeed, experimental and clinical hyperthyroidism is often accompanied by abnormal glucose tolerance. A common characteristic of hyperthyroidism and type 2 diabetes is the altered mitochondrial efficiency caused by the enhanced production of reactive oxygen and nitrogen species. It is known that an excess of thyroid hormone leads to increased oxidant production and mitochondrial oxidative damage. It can be hypothesised that these species represent the link between hype…

0301 basic medicinemedicine.medical_specialtyendocrine systemendocrine system diseasesmedicine.medical_treatmentDiabetes hyperthyroidism insulin resistance insulin secretion reactive nitrogen species (RNS) reactive oxygen species (ROS)Type 2 diabetesCarbohydrate metabolismBiochemistryHyperthyroidism03 medical and health sciencesInsulin resistanceDiabetes mellitusInternal medicinemedicineHumansGlycemic030102 biochemistry & molecular biologyChemistryInsulinThyroidGeneral Medicinemedicine.diseaseReactive Nitrogen SpeciesOxygen030104 developmental biologymedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 2Insulin ResistanceReactive Oxygen SpeciesHormoneFree radical research
researchProduct

Does high sugar consumption exacerbate cardiometabolic risk factors and increase the risk of type 2 diabetes and cardiovascular disease?

2012

Consumption of sugar has been relatively high in the Nordic countries; the impact of sugar intake onmetabolic risk factors and related diseases has been debated. The objectives were to assess the effect of sugarintake (sugar-sweetened beverages, sucrose and fructose) on association with type 2 diabetes, cardiovasculardisease and related metabolic risk factors (impaired glucose tolerance, insulin sensitivity, dyslipidemia, bloodpressure, uric acid, inflammation markers), and on all-cause mortality, through a systematic review ofprospective cohort studies and randomised controlled intervention studies published between January 2000and search dates. The methods adopted were as follows: the fir…

0301 basic medicinemedicine.medical_specialtylcsh:TX341-641030209 endocrinology & metabolismType 2 diabetesDiseaseReview ArticleVDP::Medical disciplines: 700::Health sciences: 800::Nutrition: 811fructoseImpaired glucose tolerance03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNordic nutrition recommendationssystematic reviewInternal medicinemedicineProspective cohort study030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseBlood pressurechemistrysugarUric acidbusinesssugar-sweetened beverageslcsh:Nutrition. Foods and food supplyDyslipidemiaFood ScienceCohort studyFoodnutrition research
researchProduct

Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors

2019

Cardiovascular (CV) adverse events are considered common complications of ponatinib treatment. Recently, it has been demonstrated that ponatinib dose reductions in definite settings can obtain optimal responses and lower ponatinib-related CV events. In this study, we describe the management of 5 patients with chronic myeloid leukemia treated with ponatinib, from second to fourth line of tyrosine kinase inhibitor therapy, carrying high pre-ponatinib CV risk, who obtained optimal molecular response and developed no CV adverse event during follow-up. Among these 5 patients, 2 had diagnosis of ischemic heart disease and underwent percutaneous angioplasty, 2 had type 2 diabetes and arterial hype…

0301 basic medicinemedicine.medical_specialtymedicine.drug_class030106 microbiologyCardiovascular risk factorsType 2 diabetesDiseaseTyrosine-kinase inhibitorSettore MED/15 - Malattie Del Sangue03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoverymedicinePharmacology (medical)In patientAdverse effectPharmacologybusiness.industryPonatinibChronic myeloid leukemiaMyeloid leukemiaGeneral Medicinemedicine.diseaseCardiovascular riskInfectious DiseasesOncologychemistry030220 oncology & carcinogenesisPonatinibbusiness
researchProduct